Ade LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Ade LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 6.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 275 shares of the company’s stock after buying an additional 16 shares during the quarter. Ade LLC’s holdings in Eli Lilly and Company were worth $212,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Beck Bode LLC bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $15,036,000. Sfmg LLC raised its holdings in Eli Lilly and Company by 5.8% in the second quarter. Sfmg LLC now owns 3,219 shares of the company’s stock worth $2,915,000 after purchasing an additional 177 shares in the last quarter. Royal Capital Wealth Management LLC lifted its position in Eli Lilly and Company by 5.2% during the second quarter. Royal Capital Wealth Management LLC now owns 3,869 shares of the company’s stock valued at $3,502,000 after buying an additional 191 shares during the period. Insigneo Advisory Services LLC boosted its holdings in shares of Eli Lilly and Company by 14.9% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,000 shares of the company’s stock valued at $6,338,000 after buying an additional 908 shares in the last quarter. Finally, Wescott Financial Advisory Group LLC grew its position in shares of Eli Lilly and Company by 8.7% in the 2nd quarter. Wescott Financial Advisory Group LLC now owns 9,274 shares of the company’s stock worth $8,396,000 after buying an additional 744 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Finally, Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target for the company. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Stock Up 1.5 %

Eli Lilly and Company stock opened at $753.65 on Thursday. The stock has a market cap of $715.46 billion, a PE ratio of 81.48, a price-to-earnings-growth ratio of 1.52 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a fifty day moving average of $777.46 and a 200 day moving average of $851.61. Eli Lilly and Company has a one year low of $614.82 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.98 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.80%. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.